FOLH1 and neoplasm: Further promising nuclides are under evaluation, such as [212Pb]Pb-PSMA which is an alpha emitter enabling post-injection biodistribution imaging [55], and [161Tb]Tb-PSMA a beta minus nuclide (with higher energy than [177Lu]Lu) able to co-emit Auger particles and conversion electrons theoretically resulting in disseminated higher tumor-absorbed doses [56]; however, until now published data and listed ongoing trials are limited to the CRPC stage of disease.